

DR. REDDY'S LABORATORIES LTD.

8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India.

CONTACT	
INVESTOR RELATIONS	MEDIA RELATIONS
KEDAR UPADHYE kedaru@drreddys.com (Ph: +91-40-66834297)	CALVIN PRINTER calvinprinter@drreddys.com (Ph: +91-40- 49002121)

$\tilde{0}\ \tilde{0}\ \tilde{0}$

Dr. Reddy's and TR-Pharm Announce Strategic Collaboration in Turkey

Dr Reddy's and TR-Pharm entered into a strategic collaboration agreement for manufacture and commercialization of a portfolio of biosimilar drugs in Turkey

Hyderabad, India, March 11, 2016
For Immediate Release

٥..٥.٥
٥.٥
٥.٥
٥.٥
٥.٥
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥.0
٥

Hyderbad, India, March 11, 2016: Dr. Reddyc Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and TR-Pharm announced today a strategic collaboration agreement involving 3 biosimilar products. A total of three products will be registered and subsequently commercialized as a part of this agreement by TR-Pharm in Turkey. TR-Pharm will also manufacture the drug substance and drug product upon completition of its facility investment.

Mehmet Göker, General Manager of TR-Pharm, said Biosimilars are a key component of our investment strategy in Turkey to establish biotechnological API production for national use and regional exports. This agreement will not only enable more affordable medication but also support our research and development initiatives by building expertise within the country. We are pleased to have already started laying out the groundwork for manufacturing with Dr. Reddyc for high quality biosimilar products.+

TR-Pharm has begun laying out the groundwork for the technology transfer. This collaboration will be an important component of TR-Pharmos ongoing biological product development and manufacturing business in the region. The partnership will also enable Dr. Reddyos to widen the global footprint of its biosimilar business.

About Dr. Reddy's: Dr. Reddy**\$** Laboratories Ltd. (NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products . Dr. Reddy**\$** offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infectives. Dr. Reddy**\$** operates in markets across the globe. Our major markets include . USA, Russia & CIS, Venezuela and India. For more information, log on to: <u>www.drreddys.com</u>

TR Pharm focuses on the launch of new and innovative medicines starting from registration and accomplishment of clinical programs in all phases, as well as building a biotech manufacturing facility in Turkey for the supply of monoclonal antibodies to CIS and MENA region besides the local market. TR Pharm has a wide product portfolio, led by oncology, virology, inflammatory and rare diseases. For more information: www.trpharm.com

defaults, currency exchange rates, interest rates, persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues.

The company assumes no obligation to update any information contained herein.